ST LOUIS/CAPE GIRARDEAU CCOP

圣路易斯开普吉拉多CCOP是一个由五家医院组成的财团，位于密苏里州东部和伊利诺斯州西部两个独立的两州卫生服务区。 来自圣路易斯大都会区（包括伊利诺伊州奥尔顿）的研究人员隶属于该联盟中的三家医院中的一家或多家，并在过去的15年中共同致力于癌症治疗研究方案，最近还参与了癌症控制研究。 吉拉多角的调查人员在过去的九年里一直与CCOP合作，并隶属于该市的两家医院。 在接下来的五年里，我们预计每年至少为NSABP和SWOG的癌症治疗研究方案积累80个学分，每年至少为癌症控制和预防研究积累75个学分（新参与者和随访）。 这些癌症控制积分将主要来自我们参与的乳腺癌预防试验-1、前列腺癌预防试验-1和乳腺癌预防试验-2，前提是我们被选为研究中心。我们将继续利用过去15年开发的数据管理系统，为我们的研究基地西南肿瘤组和国家外科辅助乳腺计划提供高质量的数据。总之，我们将继续我们在过去15年中在癌症治疗研究方面的出色表现，并扩大我们最近在癌症控制和预防试验中的参与。 研究者和临床研究助理过去的经验和能力为社区临床肿瘤学项目的持续发展提供了坚实的基础。

The St. Louis-Cape Girardeau CCOP is a consortium of five hospitals in two separate bi-state health service areas in eastern Missouri and western Illinois. The Investigators from the St. Louis Metropolitan area, which includes Alton, Illinois, are affiliated with one or more of three hospitals in the consortium and have worked together for the past fifteen years in cancer treatment research protocols and more recently, in cancer control research studies. The Cape Girardeau Investigators have worked with CCOP for the past nine years and are affiliated with two hospitals in that city. During the next five years we expect to accrue at least eighty credits per year for cancer treatment research protocols of the NSABP and SWOG and at least seventy five credits (new participants and follow-up) per year for cancer control and prevention studies. These cancer control credits will be derived primarily from our participation in the Breast Cancer Prevention Trial-1, Prostate Cancer Prevention Trial-1 and the Breast Cancer Prevention Trial-2 provided we are chosen as a site. We will continue to provide high quality data to the Southwest Oncology Group and the National Surgical Adjuvant Breast Program which are our research bases, utilizing the data management system developed during the past fifteen years. In summary, we will continue our excellent performance of the last fifteen years in cancer treatment research studies and extend our more recent participation in cancer control and prevention trials as well. The past experience and capabilities of the Investigators and Clinical Research Associates provides a strong base for continuing development of this Community Clinical Oncology Program.